The clinical history of Fosgonimeton (Phase 2 and Phase 2/3 failures in 2022, 2023, and 2024 across mild-to-moderate Alzheimers disease and Parkinsons disease dementia / dementia with Lewy bodies) is not direct evidence about Dihexa
B12 is also used by the immune system - so not having enough leads to higher rates of infection but also means that some of the responses that we associate with being unwell (which are actually the immune system fighting the infection) - like runny nose, rashes - can also seem to go into overdrive for a while
Mineralization of peptide amphiphile nanofibers and its effect on the differentiation of human mesenchymal stem cells
AOD-9604 may address exactly that problem
Jedicke N, Struever N, Aggrawal N, et al
Personalize Your Formula Get the latest updates and exclusive offers by subscribing to our newsletter